Emcure Pharma

Which are the latest news on Emcure Pharma?

Why is Emcure Pharmaceuticals Ltd falling/rising?

As of 05-Sep, Emcure Pharmaceuticals Ltd's stock price is rising to 1,928.55, up 3.79%, driven by strong financial metrics, positive market sentiment, and increased institutional investor participation. The stock has shown consistent gains and outperformed its sector, reflecting robust growth and investor confidence.

As of 05-Sep, Emcure Pharmaceuticals Ltd's stock price is rising, currently at 1,928.55, reflecting an increase of 70.45 or 3.79%. This upward movement can be attributed to several factors. The stock has outperformed its sector by 4.47% today and has shown consistent gains over the last three days, accumulating a total return of 4.71% during this period. Additionally, the stock reached an intraday high of Rs 1933, marking a rise of 4.03%.<BR><BR>The company's performance is also supported by its strong financial metrics, including a high return on capital employed (ROCE) of 21.82% and a low debt to EBITDA ratio of 0.84 times, indicating efficient management and a solid ability to service debt. Furthermore, Emcure Pharmaceuticals has demonstrated healthy long-term growth, with operating profit increasing at an annual rate of 29.20%. <BR><BR>Recent positive results, including a profit after tax (PAT) of Rs 530.02 crore, which grew by 30.43%, and record net sales of Rs 2,580.45 crore, have likely contributed to investor confidence. The increasing participation of institutional investors, who have raised their stake by 3.89% in the last quarter, further supports the stock's upward trajectory, as these investors typically possess greater analytical capabilities regarding company fundamentals.<BR><BR>Overall, the combination of strong financial performance, positive market sentiment, and institutional support has led to the rising stock price of Emcure Pharmaceuticals Ltd.

What does Emcure Pharma do?

Emcure Pharmaceuticals Ltd is a small-cap company in the Pharmaceuticals & Biotechnology industry, reporting net sales of 2,580 Cr and a net profit of 294 Cr for June 2026. It has a market cap of INR 35,186 Cr and key metrics include a P/E of 34.00 and a debt-equity ratio of 0.28.

Overview: <BR>Emcure Pharmaceuticals Ltd is a small-cap company operating in the Pharmaceuticals & Biotechnology industry.<BR><BR>History: <BR>Emcure Pharmaceuticals Limited was originally incorporated in 1981 as a private company and later converted into a public company in 2001. The latest quarterly results reported net sales and net profit for June 2026.<BR><BR>Financial Snapshot: <BR>Net Sales: 2,580 Cr (Quarterly Results - Jun 2026) <BR>Net Profit: 294 Cr (Quarterly Results - Jun 2026) <BR>Market Cap: INR 35,186 Cr (Small Cap)<BR><BR>Key Metrics: <BR>P/E: 34.00 <BR>Industry P/E: 37 <BR>Dividend Yield: 0.00% <BR>Debt-Equity: 0.28 <BR>Return on Equity: 19.15% <BR>Price to Book: 7.24 <BR><BR>Contact Details: <BR>Registrar Address: Not available. <BR>Phone: N/A <BR>Email: N/A <BR>Website: N/A

Who are the peers of the Emcure Pharma?

Emcure Pharma's peers include Glaxosmi Pharma, Anthem Bioscienc, Ipca Labs, Gland Pharma, Ajanta Pharma, Sai Life, Wockhardt, Neuland Labs, and Piramal Pharma. Emcure has good management risk, a good capital structure, and a 1-year return of 33.39%, higher than Piramal Pharma but lower than Sai Life's 76.70%.

Peers: The peers of Emcure Pharma are Glaxosmi. Pharma, Anthem Bioscienc, Ipca Labs, Gland Pharma, Ajanta Pharma, Sai Life, Wockhardt, Neuland Labs., and Piramal Pharma.<BR><BR>Quality Snapshot: Excellent management risk is observed at Glaxosmi. Pharma and Ajanta Pharma, while Good management risk is found at Anthem Bioscienc, Ipca Labs, Gland Pharma, Neuland Labs., and Emcure Pharma. Average management risk is present at Sai Life and Wockhardt, and the rest have Average management risk. Growth is Excellent at Anthem Bioscienc, Emcure Pharma, Sai Life, and Neuland Labs., while Below Average growth is noted at Glaxosmi. Pharma, Ipca Labs, Gland Pharma, Ajanta Pharma, and Piramal Pharma. Capital Structure is Excellent at Glaxosmi. Pharma, Anthem Bioscienc, Ipca Labs, Gland Pharma, Sai Life, and Neuland Labs., while Good capital structure is found at Emcure Pharma, and Below Average at Wockhardt and Piramal Pharma.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Sai Life at 76.70%, while the lowest is Piramal Pharma at 16.80%. Emcure Pharma's 1-year return is 33.39%, which is higher than Piramal Pharma but lower than Sai Life. Additionally, Wockhardt is the only peer with a negative six-month return.

How big is Emcure Pharma?

As of 31st August, Emcure Pharmaceuticals Ltd has a market capitalization of 35,186.00 Cr, with recent net sales of 9,683.45 Cr and a net profit of 1,011.38 Cr.

As of 31st August, Emcure Pharmaceuticals Ltd has a market capitalization of 35,186.00 Cr, categorizing it as a Small Cap company.<BR><BR>In the latest four quarters, Emcure Pharmaceuticals reported Net Sales of 9,683.45 Cr and a Net Profit of 1,011.38 Cr.<BR><BR>The latest annual period for the balance sheet is March 2025, with Shareholder's Funds amounting to 4,446.19 Cr and Total Assets of 8,121.73 Cr.

Should I buy, sell or hold Emcure Pharmaceuticals Ltd?

Are Emcure Pharmaceuticals Ltd latest results good or bad?

Emcure Pharmaceuticals Ltd's latest results show strong revenue growth with a net profit increase of 28.81% and net sales up by 16.70%. However, declining operating margins and rising interest expenses indicate potential operational challenges that investors should consider.

Emcure Pharmaceuticals Ltd's latest results present a mixed picture. On the positive side, the company reported a net profit of ₹243.40 crores for Q4 FY26, reflecting a strong year-on-year growth of 28.81%. Additionally, net sales reached ₹2,469.70 crores, marking a robust 16.70% increase compared to the same quarter last year. This indicates solid revenue growth and the company's ability to capture market share.<BR><BR>However, there are concerns regarding margin pressures. The operating margin (excluding other income) decreased to 19.42%, down from 20.85% in the previous quarter, indicating challenges in maintaining profitability amidst rising costs. Furthermore, interest expenses surged to ₹46.40 crores, representing a significant increase, which could impact future profitability.<BR><BR>Overall, while the revenue and profit growth are commendable, the decline in operating margins and rising interest costs suggest that the company is facing operational challenges. Investors may need to weigh these factors carefully when assessing the company's performance.

When is the next results date for Emcure Pharmaceuticals Ltd?

The next results date for Emcure Pharmaceuticals Ltd is 05 May 2026.

The next results date for Emcure Pharmaceuticals Ltd is scheduled for 05 May 2026.

How has been the historical performance of Emcure Pharma?

Emcure Pharma has demonstrated strong historical performance, with net sales increasing from 5,985.81 Cr in March 2023 to 7,896.00 Cr in March 2025, alongside rising profits and improved earnings per share. Despite a decline in cash flow from operating activities, the overall financial metrics indicate robust growth in sales and profitability.

Answer:<BR>Emcure Pharma has shown a positive trend in its historical performance, with significant growth in net sales and profits over the past three years.<BR><BR>Breakdown:<BR>In the fiscal year ending March 2025, Emcure Pharma reported net sales of 7,896.00 Cr, an increase from 6,658.25 Cr in March 2024 and 5,985.81 Cr in March 2023. The total operating income mirrored this growth, reaching 7,896.00 Cr in March 2025. The company's total expenditure also rose to 6,421.62 Cr, up from 5,428.53 Cr in the previous year. Operating profit (PBDIT) increased to 1,541.64 Cr in March 2025, compared to 1,286.71 Cr in March 2024. Profit before tax reached 971.35 Cr, up from 727.23 Cr, and profit after tax was 707.47 Cr, an increase from 527.58 Cr in the prior year. The consolidated net profit for March 2025 was reported at 681.33 Cr, up from 498.18 Cr in March 2024. The company's earnings per share also improved, reaching 35.96 in March 2025 from 27.5 in March 2024. On the balance sheet, total assets increased to 8,121.73 Cr in March 2025, while total liabilities rose to 8,121.73 Cr as well. The cash flow from operating activities was 851.00 Cr, down from 1,097.00 Cr in the previous year, resulting in a net cash outflow of 58.00 Cr for March 2025. Overall, Emcure Pharma's financial metrics indicate a robust growth trajectory in sales and profitability, despite some fluctuations in cash flow.

Is Emcure Pharma technically bullish or bearish?

As of November 4, 2025, Emcure Pharma shows a mildly bullish trend overall, despite some bearish signals from weekly indicators like MACD and Bollinger Bands.

As of 4 November 2025, the technical trend for Emcure Pharma has changed from sideways to mildly bullish. The daily moving averages indicate a mildly bullish stance, while the weekly MACD and Bollinger Bands are showing mildly bearish signals. The RSI has no signal on both the weekly and monthly time frames, suggesting a lack of momentum. Overall, the current technical stance is mildly bullish, but the strength is tempered by bearish indicators on the weekly charts.

Is Emcure Pharma overvalued or undervalued?

As of September 23, 2025, Emcure Pharma is considered overvalued with a PE Ratio of 33.30, an EV to EBITDA of 16.59, and a Price to Book Value of 5.65, underperforming the Sensex with a year-to-date return of -8.07%.

As of 23 September 2025, Emcure Pharma's valuation grade has moved from very expensive to expensive. The company is currently considered overvalued based on its financial metrics. Key ratios include a PE Ratio of 33.30, an EV to EBITDA of 16.59, and a Price to Book Value of 5.65. <BR><BR>In comparison to its peers, Emcure Pharma's PE Ratio is slightly lower than Sun Pharma's 34.11 but significantly higher than Cipla's 22.93, indicating a premium valuation relative to some competitors. Additionally, Emcure's PEG Ratio stands at 0.00, which is notably lower than the industry average, suggesting potential growth concerns. Recent stock performance has underperformed against the Sensex, with a year-to-date return of -8.07% compared to the Sensex's gain of 5.07%, reinforcing the notion that the stock may be overvalued.

Who are the top shareholders of the Emcure Pharma?

The top shareholders of Emcure Pharma include Satish R Mehta with 39.79%, Bc Investments IV Limited at 8.68%, and individual investors with 5.51%. Mutual funds hold 2.73%, while foreign institutional investors own 3.07%, with pledged promoter holdings at 0.0406%.

The top shareholders of Emcure Pharma include the promoters, with Satish R Mehta holding the highest stake at 39.79%. Other significant shareholders are Bc Investments IV Limited, which holds 8.68%, and individual investors who collectively own 5.51%. Additionally, mutual funds have a presence with 21 schemes holding 2.73%, while foreign institutional investors (FIIs) hold 3.07% through 48 different entities. The pledged promoter holdings are relatively low at 0.0406%.

Has Emcure Pharma declared dividend?

No Dividend History Available